Healios K.K.
Healios K.K. (HLOSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hlosf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Healios K.K. (HLOSF) measures how much investors pay for each dollar of the company's trailing earnings. HLOSF's current PE ratio of N/A is calculated by dividing its stock price of $2.70 by its TTM earnings per share of -$24.91.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Healios K.K.You HLOSF | $291M | N/A | — | -$24.91 |
 Avacta Group Plc AVCTF | $437M | N/A | — | -$0.10 |
 BioInvent International AB (publ) BOVNF | $436M | N/A | — | -$5.05 |
 Clinuvel Pharmaceuticals Limited CLVLY | $328M | 14.30x | -76.8% | $0.72 |
 Cellectis S.A. CMVLF | $251M | N/A | — | -$0.70 |
 Cresco Labs Inc. CRLBF | $333M | N/A | — | -$0.42 |
 CytoDyn Inc. CYDY | $409M | 109.11x | +76.8% | $0.00 |
Industry Average 2 peers with valid PE | — | 61.71x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-20.61 | — | |
2024-12-31 FY2024 | — | $-47.87 | — | |
2023-12-31 FY2023 | — | $-56.22 | — | |
2022-12-31 FY2022 | — | $-90.69 | — | |
2021-12-31 FY2021 | — | $-93.40 | — | |
2020-12-31 FY2020 | — | $-107.21 | — | |
2019-12-31 FY2019 | — | $-87.94 | — | |
2018-12-31 FY2018 | — | $-103.52 | — | |
2017-12-31 FY2017 | — | $-39.73 | — | |
2016-12-31 FY2016 | — | $-84.33 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Healios K.K. (HLOSF) measures how much investors pay for each dollar of the company's trailing earnings. HLOSF's current PE ratio of N/A is calculated by dividing its stock price of $2.70 by its TTM earnings per share of -$24.91.
Frequently asked questions
HLOSF pe ratio · 6 questionsHLOSF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.70 and TTM EPS of -$24.91. Data sourced from Financial Modeling Prep via HLOSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Healios K.K. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09